| Literature DB >> 12730331 |
Tomohiro Yoshikawa1, Tomohiro Ide, Hitoshi Shimano, Naoya Yahagi, Michiyo Amemiya-Kudo, Takashi Matsuzaka, Shigeru Yatoh, Tetsuya Kitamine, Hiroaki Okazaki, Yoshiaki Tamura, Motohiro Sekiya, Akimitsu Takahashi, Alyssa H Hasty, Ryuichiro Sato, Hirohito Sone, Jun-Ichi Osuga, Shun Ishibashi, Nobuhiro Yamada.
Abstract
Liver X receptors (LXRs) and peroxisome proliferator-activated receptors (PPARs) are members of nuclear receptors that form obligate heterodimers with retinoid X receptors (RXRs). These nuclear receptors play crucial roles in the regulation of fatty acid metabolism: LXRs activate expression of sterol regulatory element-binding protein 1c (SREBP-1c), a dominant lipogenic gene regulator, whereas PPARalpha promotes fatty acid beta-oxidation genes. In the current study, effects of PPARs on the LXR-SREBP-1c pathway were investigated. Luciferase assays in human embryonic kidney 293 cells showed that overexpression of PPARalpha and gamma dose-dependently inhibited SREBP-1c promoter activity induced by LXR. Deletion and mutation studies demonstrated that the two LXR response elements (LXREs) in the SREBP-1c promoter region are responsible for this inhibitory effect of PPARs. Gel shift assays indicated that PPARs reduce binding of LXR/RXR to LXRE. PPARalpha-selective agonist enhanced these inhibitory effects. Supplementation with RXR attenuated these inhibitions by PPARs in luciferase and gel shift assays, implicating receptor interaction among LXR, PPAR, and RXR as a plausible mechanism. Competition of PPARalpha ligand with LXR ligand was observed in LXR/RXR binding to LXRE in gel shift assay, in LXR/RXR formation in nuclear extracts by coimmunoprecipitation, and in gene expression of SREBP-1c by Northern blot analysis of rat primary hepatocytes and mouse liver RNA. These data suggest that PPARalpha activation can suppress LXR-SREBP-1c pathway through reduction of LXR/RXR formation, proposing a novel transcription factor cross-talk between LXR and PPARalpha in hepatic lipid homeostasis.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12730331 DOI: 10.1210/me.2002-0190
Source DB: PubMed Journal: Mol Endocrinol ISSN: 0888-8809